Washington DC ArchAngels: Peer Review & Company Discussion
Time & Location
About the Event
Washington DC ArchAngels RSVP Requested - Invitation Only (REGISTRATION IS REQUIRED)
Company Description Tosk Inc. provides new drugs that prevent undesirable side effects of widely-used cancer therapies and to block proteins produced by cancer genes that drive tumor growth. Using innovative Drosophila fly-based drug discovery methods, the company has initially identified two compounds (TK-90 and TK-39) that prevent adverse effects of cancer treatment, with important patient benefits such as avoiding decisions to terminate therapy due to severe side effects. Both products address dose limiting and potentially fatal adverse side effects including mucositis, cardiotoxicity, and nephrotoxicity. Mucositis is a significant side effect of leading cancer treatments such as methotrexate and radiation, therapies often used for breast, colon, head and neck, pancreatic cancers and leukemia. Currently, the TK-90 compound has completed “proof of concept” in FDA Phase 2a clinical studies in head and neck cancer patients and also has applications outside of cancer including Covid 19. TK-39 has completed preclinical efficacy testing. Management team strengths include extensive experience in entrepreneurial enterprises (co-founders of a diagnostic and 3 therapeutic companies, and several other early-stage biotechnology companies) and drug research and development (Roche, Affymax, Bell Labs, Chemocentryx and Amunix). The company's primary business development strategy is focused on its discovery platform and identifying proprietary, small molecule drugs and moving drug development through proof of concept in human clinical studies, and followed by seeking partnerships with larger pharmaceutical companies. Based on current progress in its initial drug discovery and development, the company expects to achieve a partnered Phase 3 drug and two Phase 2 drugs in the pipeline within 18 months.
Meeting ID: 967 2812 9644
Audio only - phone dial in numbers:
➡ 646-876 9923 US (New York) ➡ 301-715-8592 US (Maryland) ➡ 312-626-6799 US (Chicago) ➡ 669-900-6833 US (California)firstname.lastname@example.org Thanks, Dan Loague President Washington DC Archangels Cell: 405-824-5549